Mesguich C - Search Results

1

Role of ¹⁸F-FDG PET/CT in Posttreatment Evaluation of Anal Carcinoma.

Houard C, Pinaquy JB, Mesguich C, Henriques de Figueiredo B, Cazeau AL, Allard JB, Laharie H, Bordenave L, Fernandez P, Vendrely V. Houard C, et al. Among authors: mesguich c. J Nucl Med. 2017 Sep;58(9):1414-1420. doi: 10.2967/jnumed.116.185280. Epub 2017 Mar 9. J Nucl Med. 2017. PMID: 28280225 Free article.

2

State of the art imaging of multiple myeloma: comparative review of FDG PET/CT imaging in various clinical settings.

Mesguich C, Fardanesh R, Tanenbaum L, Chari A, Jagannath S, Kostakoglu L. Mesguich C, et al. Eur J Radiol. 2014 Dec;83(12):2203-2223. doi: 10.1016/j.ejrad.2014.09.012. Epub 2014 Sep 28. Eur J Radiol. 2014. PMID: 25308249 Review.

3

High performances of (18)F-fluorodeoxyglucose PET-CT in cardiac implantable device infections: A study of 40 patients.

Tlili G, Amraoui S, Mesguich C, Rivière A, Bordachar P, Hindié E, Bordenave L. Tlili G, et al. Among authors: mesguich c. J Nucl Cardiol. 2015 Aug;22(4):787-98. doi: 10.1007/s12350-015-0067-x. Epub 2015 Mar 19. J Nucl Cardiol. 2015. PMID: 25788402

4

Erratum to: High performances of (18)F-fluorodeoxyglucose PET-CT in cardiac implantable device infections: A study of 40 patients.

Tlili G, Amraoui S, Mesguich C, Rivière A, Bordachar P, Hindié E, Bordenave L. Tlili G, et al. Among authors: mesguich c. J Nucl Cardiol. 2015 Aug;22(4):799. doi: 10.1007/s12350-015-0190-8. J Nucl Cardiol. 2015. PMID: 26041258 No abstract available.

5

New Perspectives Offered by Nuclear Medicine for the Imaging and Therapy of Multiple Myeloma.

Mesguich C, Zanotti-Fregonara P, Hindié E. Mesguich C, et al. Theranostics. 2016 Jan 1;6(2):287-90. doi: 10.7150/thno.14400. eCollection 2016. Theranostics. 2016. PMID: 26877786 Free PMC article.

6

Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation.

Mesguich C, Cazeau AL, Bouabdallah K, Soubeyran P, Guyot M, Milpied N, Bordenave L, Hindié E. Mesguich C, et al. Br J Haematol. 2016 Nov;175(4):652-660. doi: 10.1111/bjh.14292. Epub 2016 Aug 19. Br J Haematol. 2016. PMID: 27539369 Free article.

7

The impact of combination of regadenoson and isometric exercise on image quality of myocardial perfusion scintigraphy.

Ceyrat Q, Mesguich C, Janvier L, Douard H, Bordenave L, Pinaquy JB. Ceyrat Q, et al. Among authors: mesguich c. J Nucl Cardiol. 2017 Jun;24(3):993-997. doi: 10.1007/s12350-016-0711-0. Epub 2016 Nov 1. J Nucl Cardiol. 2017. PMID: 27804069 No abstract available.

8

Hodgkin lymphoma: is there really a need for interim and end-of-treatment FDG-PET evaluations? - Response to Adams & Kwee.

Mesguich C, Cazeau AL, Bouabdallah K, Hindié E. Mesguich C, et al. Br J Haematol. 2018 Apr;181(1):124-125. doi: 10.1111/bjh.14494. Epub 2017 Jan 20. Br J Haematol. 2018. PMID: 28106255 Free article. No abstract available.

9

Advanced Hodgkin's lymphoma: End-of-treatment FDG-PET should be maintained.

Hindié E, Mesguich C, Bouabdallah K, Milpied N. Hindié E, et al. Among authors: mesguich c. Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1254-1257. doi: 10.1007/s00259-017-3714-4. Eur J Nucl Med Mol Imaging. 2017. PMID: 28466283 No abstract available.

10

Response to the letter by Adams and Kwee, entitled: "Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma".

Hindié E, Mesguich C, Bouabdallah K, Milpied N. Hindié E, et al. Among authors: mesguich c. Eur J Nucl Med Mol Imaging. 2017 Oct;44(11):1937-1939. doi: 10.1007/s00259-017-3773-6. Eur J Nucl Med Mol Imaging. 2017. PMID: 28707119 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

28 results

Search Page

Filters